High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kentuckiana Cancer Institute
• Treatments: Camptothecin; Irinotecan

Criteria

Inclusion Criteria:

• recurrent, unresectable primary CNS neoplasm per MRI

• ECOG status of 2 or less

• no prior therapy with camptothecans

• on an enzyme-inducing antiepileptic